Sentences with phrase «may generic drug company»

In May generic drug company Actavis Inc. agreed to buy Warner Chilcott PLC for $ 8.5 billion in stock, creating the third - biggest specialty pharmaceutical company in the U.S. market.

Not exact matches

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Allergan would also bolster Pfizer's «innovative» (i.e. brand - name) drug business, which it internally separated from its slower - growing «established» (i.e. generic and non-patented) drug division in 2014, further signaling that it may be planning to split into two different companies altogether.

A company with lots of pending ANDS relative to its competitors may end up with more generic drugs to sell and therefore be more profitable.

Generic drug makers may be the «new defensive» plays in modern times, but anyone who has owned either generic drug companies or «big pharma» drug companies over the last 10 to 12 years can affirm that this defensive stock stigma is not as true as the classical business models used to inGeneric drug makers may be the «new defensive» plays in modern times, but anyone who has owned either generic drug companies or «big pharma» drug companies over the last 10 to 12 years can affirm that this defensive stock stigma is not as true as the classical business models used to ingeneric drug companies or «big pharma» drug companies over the last 10 to 12 years can affirm that this defensive stock stigma is not as true as the classical business models used to indicate.

Plaintiff May Sue Manufacturer of Name - Brand Prescription Drug for Injury Allegedly Caused by Different Company's Generic Drug, Indiana Injury Lawyer Blog, February 28, 2013 Federal Statute Preempts State Products Liability Lawsuit Over Asbestos Exposure, According to Supreme Court: Kurns v. Railroad Friction Products Corp., Indiana Injury Lawyer Blog, October 18, 2012

In its May 13, 2014 Statement, the Bureau stated that «product life - cycle management strategies in the pharmaceutical sector are not inherently anti-competitive... However, life - cycle management strategies that are designed to impede competition from generic drug companies, such as product switching strategies, may cause significant harm to competition.&raqMay 13, 2014 Statement, the Bureau stated that «product life - cycle management strategies in the pharmaceutical sector are not inherently anti-competitive... However, life - cycle management strategies that are designed to impede competition from generic drug companies, such as product switching strategies, may cause significant harm to competition.&raqmay cause significant harm to competition.»